{"id":"mvc-cov1901","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL265515","moleculeType":"Small molecule","molecularWeight":"224.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant SARS-CoV-2 spike protein produced in insect cells, formulated with an adjuvant to enhance immunogenicity. It is designed to elicit both humoral (antibody) and cellular (T-cell) immune responses against the spike protein, enabling the body to recognize and neutralize the virus upon exposure.","oneSentence":"MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:19.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"trialDetails":[{"nctId":"NCT05054621","phase":"PHASE2","title":"Immunogenicity of COVID-19 Vaccine on Heterologous Schedule","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-09-15","conditions":"Covid-19, Vaccine, Immunogenicity","enrollment":100},{"nctId":"NCT05079633","phase":"PHASE4","title":"A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-09-30","conditions":"Covid19 Vaccine","enrollment":220},{"nctId":"NCT05198596","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-30","conditions":"COVID-19 Vaccine","enrollment":250},{"nctId":"NCT05426343","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-07-09","conditions":"COVID-19 Vaccine","enrollment":200},{"nctId":"NCT05216601","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-05-06","conditions":"COVID-19 Vaccine","enrollment":107},{"nctId":"NCT05197153","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2022-01-22","conditions":"COVID-19 Vaccine","enrollment":804},{"nctId":"NCT05011526","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-10-08","conditions":"Covid19 Vaccine","enrollment":1030},{"nctId":"NCT05048849","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-07-19","conditions":"Covid19 Vaccine","enrollment":274},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04822025","phase":"PHASE2","title":"A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-05-20","conditions":"Covid19 Vaccine","enrollment":420},{"nctId":"NCT05038618","phase":"PHASE2","title":"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-08-02","conditions":"Covid19 Vaccine","enrollment":399},{"nctId":"NCT04951388","phase":"PHASE2","title":"A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-07-22","conditions":"Covid19 Vaccine","enrollment":399},{"nctId":"NCT04487210","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2020-10-07","conditions":"COVID-19","enrollment":45},{"nctId":"NCT04695652","phase":"PHASE2","title":"A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2020-12-30","conditions":"Covid19 Vaccine","enrollment":3854},{"nctId":"NCT05097053","phase":"PHASE4","title":"A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19","status":"UNKNOWN","sponsor":"Taoyuan General Hospital","startDate":"2021-10-07","conditions":"COVID-19 Vaccine","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MVC-COV1901","genericName":"MVC-COV1901","companyName":"Medigen Vaccine Biologics Corp.","companyId":"medigen-vaccine-biologics-corp","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}